Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Gains from Sales and Divestitures (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Gains from Sales and Divestitures for 2 consecutive years, with $521625.0 as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Gains from Sales and Divestitures rose 139.28% year-over-year to $521625.0, compared with a TTM value of $521625.0 through Dec 2023, up 139.28%, and an annual FY2023 reading of $521625.0, up 139.28% over the prior year.
  • Gains from Sales and Divestitures was $521625.0 for Q4 2023 at Oramed Pharmaceuticals, up from $218000.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $521625.0 in Q4 2023 and bottomed at $218000.0 in Q4 2022.